This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Eldad Melamed, MD

Arch Neurol. 1986;43(4):402-405.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To date, orally administered levodopa, usually in combination with a peripheral dopadecarboxylase inhibitor, remains the most potent agent in the treatment of Parkinson's disease. It is now well established that levodopa improves many of the disabling motor symptoms and signs and the quality of life, as well as life expectancy, in parkinsonian subjects.^1-5 Nevertheless, despite its widespread use for more than 15 years, a major unsettled and often heatedly debated question concerning dopa therapy still persists: ie, when should levodopa therapy be started in such patients?^6,7 More specifically, it is uncertain whether levodopa should be given to all parkinsonian patients immediately on diagnosis and regardless of the stage and severity of the disorder or whether its long-term administration should be withheld and delayed in milder cases (stages I and II according to Hoehn and Yahr⁸) and restricted to those patients who are in the more advanced stages . . . [Full Text PDF of this Article]

Author Affiliations
From the Department of Neurology and the Laboratory of Clinical Neurochemistry, Hadassah University Hospital, Jerusalem.

Footnotes
Accepted for publication May 10, 1985.

Reprint requests to Department of Neurology, Hadassah Hospital, Jerusalem, PO Box 12 000, Israel (Dr Melamed).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?